CRNX (Crinetics Pharmaceuticals, Inc.) Net Profit

Official company branding of Crinetics Pharmaceuticals, Inc. (CRNX)

Crinetics Pharmaceuticals (CRNX) is overcoming stringent FDA oversight and high development costs by implementing AI for the synthesis of endocrine drugs. The company's net reported profit on GURU.Markets reflects financial dynamics where the -0.51 metric indicates the business status. The success of venture investments and the market launch of Paltusotine will determine the future reach across medical centers.

CRNX (Crinetics Pharmaceuticals) Company Net Income history from 07/04/2022 to 09/12/2026

Comprehensive metric breakdowns and analytics for Crinetics (CRNX)

- price and consensus price forecast:
Stock Quotes Crinetics Corp|CRNX - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Crinetics Corp|CRNX - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share Crinetics|CRNX - Company Book Value|Market Cap to Net Assets Ratio crinetics.com|CRNX - Company Total Assets
- debt and solvency information:
Debt to Capital Crinetics Pharmaceuticals|CRNX - Long-Term Debt to Equity Ratio|Short-Term Loans to Capital Ratio Crinetics Pharmaceuticals, Inc.|CRNX - Company Aggregate Debts|Debts to Book Capitalization Crinetics Corp|CRNX - Company Long-Term Debts|Company Short-Term Debt Crinetics|Immediate Liquidity crinetics.com
- net income and valuation multiples indicators:
CRNX - Company Net Income
Fundamental valuation:Crinetics Pharmaceuticals
Signature product of crinetics.com

The development of drugs for rare endocrine pathologies provides Crinetics Pharmaceuticals (CRNX) with a potential monopoly in the orphan disease niche. This metric measures net daily income, allowing for an assessment of real business efficiency and the balance between current profitability and R&D investments, which makes the company's net profit trend a key indicator of the asset's fundamental value stability.

Direct competitors

Net Income Ascendis|MDGL (Madrigal Pharmaceuticals) - Net Profit|Net Profit corcept.com|Net Income RYTM (Rhythm Pharmaceuticals, Inc.)|AKRO (Akero Therapeutics, Inc.) - Final Profit|Company Net Income Metsera Corp MTSR|MLTX - Net Income|NewAmsterdam Pharma - Net Profit|Company Net Income soleno.life|FOLD (Amicus Therapeutics, Inc.) - Net Income|ETNB: Profit After Payment of Taxes|AGIO (Agios Pharmaceuticals Inc) - Net Profit|Net Profit Structure Corp|Net Profit MDXG|Company Net Income RZLT (rezolutebio.com)|Company Net Income Lexicon Pharmaceuticals, Inc. LXRX|MBX Biosciences, Inc. (MBX) - Company Net Income|ALT - Company Net Income|AARD: Company Net Income|SGMT: Net Profit|BIOA - Net Financial Result|Company Net Income Biomea Fusion|Quince (QNCX) - Net Financial Result|Company Net Income Fractyl (GUTS)|Net Income vtvtherapeutics.com VTVT|Net Profit ATPC (Agape ATP)|PLUR - Net Income|SYBX - Company Net Income|Final Profit LPCN (Lipocine Inc)|MTNB: Net Profit|SPRB - Net Financial Result|Company Net Income Galecto, Inc.|Company Profit CTCX (carmellrx.com)|Net Profit LUMO|ONVO - Company Net Income|Radius Health - Net Income